St. David’s South Austin Medical Center enrolls first patient in drug study for transplant complications

Learn more

The Sarah Cannon Blood Cancer Center at St. David’s South Austin Medical Center recently enrolled the first patient in the world to participate in a drug trial to treat a potentially fatal complication from allogeneic hematopoietic cell transplants, or stem cell transplants using donated stem cells.

The hospital is one of 130 sites worldwide to participate in this study on the drug Itacitinib, which is being investigated as a treatment for chronic graft-versus-host disease (cGVHD). cGVHD is a condition in which the peripheral blood stem cells that make up the donated bone marrow attack the patient’s healthy tissue and organs.


July 8, 2019

St. David's Medical Center